• / Free eNewsletters & Magazine
  • / My Account
Home>UPDATE: Congressman urges President Trump to take action on $90,000 multiple sclerosis drug

UPDATE: Congressman urges President Trump to take action on $90,000 multiple sclerosis drug

UPDATE: Congressman urges President Trump to take action on $90,000 multiple sclerosis drug

09/30/2017

By Emma Court

Cummings said the president could 'make a deal' to lower Zinbryta's price

Rep. Elijah Cummings (D-Md.) urged President Donald Trump to help lower the price of a $90,000-a-year multiple sclerosis drug on Thursday.

In a series of tweets, Cummings said that Trump could "make a deal" on Biogen (BIIB) and AbbVie's (ABBV) Zinbryta, because the drug was developed using technology licensed from the federal government.

"If they refuse, you can revoke their license or license the drug to more companies to lower the price today!" Cummings, who met with Trump to discuss drug prices earlier this year, said in a tweet. "Shouldn't cost $87k per year!"

Zinbryta was approved by the Food and Drug Administration in May of 2016 for relapsing forms of multiple sclerosis, a degenerative disease that disrupts the central nervous system and affects about 2.3 million people worldwide.

The nonprofit Knowledge Ecology International wrote to the Department of Health and Human Services two weeks ago asking it to consider several options to lower the drug's price, a letter that Cummings referred to on Thursday.

(https://twitter.com/RepCummings/status/913366639445516288)

©2017 Morningstar Advisor. All right reserved.